Sigma Labs Reports Third Quarter 2020 Financial Results
Back to Newsroom
Mentioned in this Article

Sigma Labs Reports Third Quarter 2020 Financial Results

Thursday, October 22, 2020 4:01 PM
Share this article now
Topic:
Earnings

Management to Host Conference Call Today at 4:30 p.m. ET

SANTA FE, NM / ACCESSWIRE / October 22, 2020 / Sigma Labs, Inc. (NASDAQ:SGLB) ("Sigma Labs"), a leading developer of quality assurance software for the commercial 3D metal printing industry, reported its financial and operational results for the third quarter ended September 30, 2020.

Key Third Quarter 2020 and Subsequent Operational Highlights

  • Appointed Steve Immel to the position of Senior Director Business Development, North America;
    • Responsible for engaging with 3D printer OEMS, additive manufacturers, academic institutions and research organizations to propel Sigma Labs PrintRite3D® in-process quality assurance solutions into production applications; and
    • Veteran of the 3D printing industry having fulfilled leadership roles at 3D Systems, Materialise and Jabil Additive.
  • Extended OEM Agreement and completed certification process designating Additive Industries' MetalFAB1 printers PrintRite3D® Ready:
    • Will begin selling PrintRite3D® Melt-Pool Monitoring solution to new and existing users of MetalFAB1 3D printers; and
    • Reduced post-processing costs, less material waste, and faster part qualification for end users.
  • Awarded contract by Major Oil and Gas Services Company:
    • To begin production deployment of PrintRite3D® in-process quality assurance software, following a successful Rapid Test and Evaluation (RTE) program; and
    • Extensive evaluation process involved running PrintRite3D® on an EOS single laser machine and an SLM dual laser machine.
  • Awarded Contract From Coherent (NASDAQ: COHR) for New PrintRite3D Lite In-Process Quality Assurance System:
    • Launched its newest product, the PrintRite3D Lite In-Process Quality Assurance (IPQA) system;
    • The PrintRite3D Lite IPQA® system was designed and developed specifically to fulfill the need for melt pool quality monitoring for the small, compact, entry level machines being used in academia, R&D, dental, and industrial small lot production; and
    • PrintRite3D Lite will be available for OEM licensing as well as third party retrofit installations.
  • Announced Strategic Alliance with IN4.OS for Factories of the Future:
    • Partnered with IN4.OS to build Smart Factories of the Future to meet the demands of high technology sectors including defense, space, aerospace and life sciences;
    • Provides flexibility in the manufacturing process to build custom mission critical parts on demand, with unprecedented complexity in times of shortages; and
    • IN4.OS will be utilizing DMG MORI's LASERTEC line of 3D metal printers, which have been designated as PrintRite3D® Ready.
  • Expanded market opportunity and announced PrintRite3D for Directed Energy Deposition (DED) additive processes:
    • New partnership with Northwestern University expands in-process quality assurance technology across a broad array of 3D printing processes;
    • DED has been successfully applied in various industries, including aerospace, oil & gas, defense, marine and architecture; and
    • Currently engaged with additional commercial DED machine OEM partners to expand beta testing program.

Management Commentary

"The third quarter of 2020 was about execution and laying the foundation for a successful 2021 and we are very pleased to have made significant progress in each of the strategic initiatives that we established at the beginning of the year," said Mark K. Ruport, President and Chief Executive Officer of Sigma Labs. "On the financial front, our balance sheet expanded during the third quarter by $3.5 million from the exercise of preferred warrants from our January 2020 private placement of convertible preferred stock and warrants. This, paired with a continued reduction in cash burn, has better positioned Sigma to weather any macro-economic storms that may arise over the coming months and extends our cash runway well into 2021.

"During the third quarter of 2020, we announced a contract with a major oil and gas services company, following a successful Rapid Test and Evaluation (RTE) program. The conversion from our RTE program to beginning production deployment is a testament to the traction our enabling technology is garnering in the additive manufacturing industry. This followed last quarter's contract with Mitsubishi Heavy Industries, a global leader in engineering and manufacturing to implement PrintRite3D. These large global manufacturers adopting PrintRite3D as their quality assurance system of choice continues to validate Sigma's technology and the need for a third party, standards-based system that can operate in a heterogeneous 3D printer environment.

"The strategic nature of our agreements with Additive Industries and Coherent combined with our partnership with DMG MORI cannot be overstated. Each provides leverage to our business model, increases our global reach, expands our footprint in the industry and adds more validation to our technology.

"We also expanded our addressable market opportunity with Printrite3D Lite and PriontRite3D DED. We are excited to have Coherent as our initial customer for PrintRite3D Lite and to work with Northwestern University, our initial customer for PrintRite3D DED. Each market offers significant opportunities for revenue growth while extending our IPQA technology across different processes on the manufacturing floor," continued Ruport.

"As we look into 2021, Sigma Labs will remain laser-focused on building leverage into our business model and expanding our reach and footprint in the industry. Our priorities are: driving multi-unit sales of PrintRite3D Production Series by end users that have validated our technology through the @Sigma RTE program; forming new strategic alliances and OEM contracts with both additive manufacturing hardware and software companies that provide sales leverage and market validation; and continued success with R&D organizations and universities. We look forward to sharing more on our developing story at upcoming investor conferences and virtual roadshows in the fourth quarter of 2020," concluded Ruport.

Third Quarter 2020 Financial Results

Revenue for the third quarter of 2020 totaled $0.25 million. This compares to revenues of $0.17 million for the third quarter of 2019. The increase in revenue was due to increased PrintRite3D® unit sales, including the first sale of a PrintRite3D Lite® unit during the quarter.

Gross profit for the third quarter of 2020 was $0.15 million as compared to negative $8 thousand in the third quarter of 2019.

Total operating expenses for the third quarter of 2020 were $1.4 million as compared to total operating expenses of $1.6 million for the same period in 2019.

Cash used in operating activities for the three months ended September 30, 2020 totaled $1.2 million compared to $1.8 million in the third quarter of 2019, a decrease of $0.6 million. Cash used in operating activities for the nine months ended September 30, 2020 totaled $3.7 million compared to $4.5 million for the first nine months of 2019. The decrease in year-to-date cash used in 2020 versus 2019 was driven primarily by a $967,161 decrease in net loss.

Net loss for the third quarter of 2020 was $1.2 million, or $(0.42) per share, as compared to a net loss of $1.6 million, or $(1.20) per share, in the third quarter of 2019.

Cash totaled $4.5 million at September 30, 2020, as compared to $2.5 million at June 30, 2020 and $1.1 million at September 30, 2019. The increase in cash during the period was a result of warrant exercises from our January 2020 private placement of convertible preferred stock and warrants.

Third Quarter 2020 Results Conference Call

Sigma Labs President and CEO Mark Ruport and CFO Frank Orzechowski will host the conference call, followed by a question and answer period.

To access the call, please use the following information:

Date:
Time:
Toll-free dial-in number:
International dial-in number:
Conference ID:

Thursday, October 22, 2020
4:30 p.m. Eastern time, 1:30 p.m. Pacific time
1-877-407-9039
1-201-689-8470
13711743

   

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.

The conference call will be broadcast live and available for replay at http://public.viavid.com/index.php?id=141888 and via the investor relations section of the Company's website at www.sigmalabsinc.com.

A replay of the conference call will be available after 7:30 p.m. Eastern time through November 5, 2020.

Toll-free replay number:
International replay number:
Replay ID:

1-844-512-2921
1-412-317-6671
13711743

   

About Sigma Labs

Sigma Labs Inc. (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D® brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D® for 3D metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process and informs the production manager of quality issues. Sigma Labs believes its software product will be a major catalyst for the acceleration and adoption of 3D metal printing. For more information, please visit www.sigmalabsinc.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors, including, but not limited to, the uncertain effect of the COVID-19 pandemic on the Sigma Labs' business, results of operations and financial condition, which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K (including but not limited to the discussion under "Risk Factors" therein) filed with the SEC on March 24, 2020 and which may be viewed at www.sec.gov.

Investor Contact:
Chris Tyson
Managing Director
MZ Group - MZ North America
949-491-8235
[email protected]
www.mzgroup.us

Company Contact:
Steven Gersten
Sigma Internal IR
813-334-9745
[email protected]

Sigma Labs, Inc.
Condensed Balance Sheets
(Unaudited)

 
  September 30, 2020     December 31,
2019
 
 
           
ASSETS
           
Current Assets:
           
Cash
  $ 4,510,548     $ 86,919  
Accounts Receivable, net
    485,067       55,540  
Inventory
    574,540       598,718  
Prepaid Assets
    144,058       199,727  
Total Current Assets
    5,714,212       940,904  
 
               
Other Assets:
               
Property and Equipment, net
    154,204       128,723  
Intangible Assets, net
    707,663       569,341  
Investment in Joint Venture
    -       500  
Long-Term Prepaid Asset
    52,000       52,000  
Total Other Assets
    913,867       750,564  
 
               
TOTAL ASSETS
  $ 6,628,079     $ 1,691,468  
 
               
LIABILITIES AND STOCKHOLDERS' EQUITY
               
 
               
Current Liabilities:
               
Accounts Payable
  $ 182,123     $ 727,114  
Notes Payable
    -       50,000  
Deferred Revenue
    92,841       139,447  
Accrued Expenses
    230,680       122,658  
Total Current Liabilities
    505,644       1,039,219  
 
               
Long-Term Liabilities:
               
CARES Act Deferred Payroll Tax Liability
    53,545       -  
Total Long-Term Liabilities
    53,545       -  
 
               
TOTAL LIABILITIES
    559,189       1,039,219  
 
               
Stockholders' Equity
               
Preferred Stock, $0.001 par; 10,000,000 shares authorized; 583 and 0 issued and outstanding, respectively
    1       -  
Common Stock, $0.001 par; 12,000,000 shares authorized; 5,833,245 and 1,403,759 issued and outstanding, respectively
    5,833       1,404  
Additional Paid-In Capital
    37,614,357       26,746,439  
Accumulated Deficit
    (31,551,301 )     (26,095,594 )
Total Stockholders' Equity
    6,068,890       652,249  
 
               
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
  $ 6,628,079     $ 1,691,468  


Sigma Labs, Inc.
Condensed Statements of Operations

(Unaudited)

 
  Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
 
  2020     2019     2020     2019  
 
                       
REVENUES
  $ 248,526     $ 171,003     $ 637,944     $ 269,035  
 
                               
COST OF REVENUE
    97,785       178,760       400,172       335,939  
 
                               
GROSS PROFIT (LOSS)
    150,741       (7,757 )     237,772       (66,904 )
 
                               
OPERATING EXPENSES:
                               
Salaries & Benefits
    657,889       644,800       1,915,381       1,738,716  
Stock-Based Compensation
    58,219       79,202       483,208       403,768  
Operating R&D Costs
    79,673       212,230       245,008       476,346  
Investor & Public Relations
    272,964       269,130       682,518       734,237  
Legal & Professional Service Fees
    100,144       116,221       530,660       519,710  
Office Expenses
    84,357       186,430       310,947       536,608  
Depreciation & Amortization
    50,167       52,636       86,150       150,222  
Other Operating Expenses
    59,100       40,265       194,836       117,470  
Total Operating Expenses
    1,362,513       1,600,914       4,448,708       4,677,077  
 
                               
LOSS FROM OPERATIONS
    (1,211,772 )     (1,608,671 )     (4,210,936 )     (4,743,981 )
 
                               
OTHER INCOME (EXPENSE)
                               
Interest Income
    77       4,812       959       17,610  
State Incentives
    -       -       151,657       51,877  
Exchange Rate Gain (Loss)
    (252 )     (549 )     (1,674 )     (3,259 )
Interest Expense
    (6,066 )     (2,149 )     (12,741 )     (6,407 )
Loss on Dissolution of Joint Venture
    -       -       (201 )     -  
Other Income
    -       5,763       361,700       5,763  
Total Other Income (Expense)
    (6,241 )     7,877       499,700       65,584  
 
                               
LOSS BEFORE PROVISION FOR INCOME TAXES
    (1,218,013 )     (1,600,794 )     (3,711,236 )     (4,678,397 )
 
                               
Provision for income Taxes
    -       -       -       -  
 
                               
Net Loss
  $ (1,218,013 )   $ (1,600,794 )   $ (3,711,236 )   $ (4,678,397 )
 
                               
Preferred Dividends
    (737,344 )     -       (1,744,471 )     -  
 
                               
Net Loss Applicable to Common Stockholders
  $ (1,955,357 )   $ (1,600,794 )   $ (5,455,707 )   $ (4,678,397 )
 
                               
Net Loss per Common Share - Basic and Diluted
  $ (0.42 )   $ (1.20 )   $ (1.74 )   $ (4.30 )
 
                               
Weighted Average Number of Shares Outstanding - Basic and Diluted
    4,675,749       1,285,160       3,137,459       1,099,627  


Sigma Labs, Inc.
Condensed Statements of Cash Flows

(Unaudited)

 
  Nine Months Ended  
 
  September 30, 2020     September 30, 2019  
OPERATING ACTIVITIES
           
Net Loss
  (3,711,236 )   (4,678,397 )
Adjustments to reconcile Net Loss to Net Cash used in operating activities:
               
Noncash Expenses:
               
Depreciation and Amortization
    86,150       150,222  
Stock Based Compensation
    483,208       403,768  
Securities Issued for Third Party Services
    113,843       17,110  
Securities Issued to Directors for Services
    131,150       225,000  
 
               
Change in assets and liabilities:
               
Accounts Receivable
    (429,527 )     (42,403 )
Interest Receivable
    -       1,391  
Inventory
    24,178       (472,501 )
Prepaid Assets
    55,669       (179,191 )
Accounts Payable
    (544,991 )     205,571  
Deferred Revenue
    (46,606 )     48,345  
Accrued Expenses
    108,022       (177,494 )
NET CASH USED IN OPERATING ACTIVITIES
    (3,730,140 )     (4,498,579 )
 
               
INVESTING ACTIVITIES
               
Purchase of Property and Equipment
    (88,074 )     (33,487 )
Purchase of Intangible Assets
    (161,878 )     (157,922 )
Payment Received from Notes Receivable
    -       120,522  
Dissolution of Joint Venture
    500       -  
NET CASH USED IN INVESTING ACTIVITIES
    (249,452 )     (70,887 )
 
               
FINANCING ACTIVITIES
               
Gross Proceeds from Public and Private Issuances of Securities
    3,600,000       4,981,220  
Less Offering Costs
    (820,224 )     (655,954 )
Payment of Note Payable
    (50,000 )     -  
Proceeds from Exercise of Warrants
    5,619,900       75,848  
Deferral of Payroll Taxes under the CARES Act
    53,545       -  
NET CASH PROVIDED BY FINANCING ACTIVITIES
    8,403,221       4,401,114  
 
               
NET CHANGE IN CASH FOR PERIOD
    4,423,629       (168,352)  
 
               
CASH AT BEGINNING OF PERIOD
    86,919       1,279,782  
 
               
CASH AT END OF PERIOD
  4,510,548     1,111,430  
 
               
Supplemental Disclosures:
               
Noncash investing and financing activities disclosure:
               
 
               
Issuance of Common Shares for Conversion of Preferred Shares and Preferred Dividends
  7,460,121     -  
Issuance of Securities for Services
  244,993     245,111  
Disclosure of cash paid for:
               
Interest
  12,741     2,514  
Income Taxes
  -     -  


SOURCE: Sigma Labs, Inc.

Sigma Labs, Inc.
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |  Terms and Conditions
Drop us a line: